Business
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant,
About this update from Immix Biopharma, Inc.
[{"type":"image","alt":"Immix Biopharma, Inc.","displaySize":"","headline":null,"caption":"Immix Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wOmQhF0jrEFCj3SbuTNPPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d","width":300,"height":93}},"lazy":false},{"type":"text","content":"LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $100 million. The offering is expected to close on or about December 9, 2025, subject to the satisfaction of customary closing conditions.","length":940,"tagName":"p"},{"type":"text","content":"Immix intends to use the net proceeds from this offering, together with its existing cash and cash equivalents to fund NXC-201 development and for working capital and general corporate purposes. Immix believes that the net proceeds from the offering, together with its existing cash and cash equivalents, and expected disbursements under the Company’s CIRM grant will be sufficient to meet the Company’s operational needs into mid-2027.","length":436,"tagName":"p"},{"type":"text","content":"Morgan Stanley is acting as the sole book-running manager for the offering. Citizens Capital Markets and Mizuho are acting as co-managers for the offering.","length":161,"tagName":"p"},{"type":"text","content":"The securities in the registered offering are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File N...